↓ Skip to main content

Liposome-mediated delivery of the p21 activated kinase-1 (PAK-1) inhibitor IPA-3 limits prostate tumor growth in vivo

Overview of attention for article published in Nanomedicine: Nanotechnology, Biology and Medicine, March 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#5 of 1,520)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
25 news outlets
blogs
3 blogs
twitter
3 X users

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
26 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Liposome-mediated delivery of the p21 activated kinase-1 (PAK-1) inhibitor IPA-3 limits prostate tumor growth in vivo
Published in
Nanomedicine: Nanotechnology, Biology and Medicine, March 2016
DOI 10.1016/j.nano.2016.01.003
Pubmed ID
Authors

Ahmad Al-Azayzih, Wided N. Missaoui, Brian S. Cummings, Payaningal R. Somanath

Abstract

P21 activated kinases-1 (PAK-1)is implicated in various diseases. It is inhibited by thesmall molecule 'Inhibitor targeting PAK1 activation-3' (IPA-3), which is highly specific but metabolically unstable. To address this limitation we encapsulatedIPA-3 in sterically stabilized liposomes (SSL). SSL-IPA-3 averaged 139 nm in diameter,polydispersity index (PDI) of 0.05, and a zeta potential of -28.1, neither of which changed over 14 days; however, the PDI increased to 0.139. Analysis of liposomal IPA-3 levels demonstrated good stability, with 70% of IPA-3 remaining after 7 days. SSL-IPA-3 inhibited prostate cancer cell growth in vitro with comparable efficacy to free IPA-3. Excitingly, only a 2 day/week dose of SSL-IPA-3 was needed to inhibit the growth of prostate xenografts in vivo, while a similar dose of free IPA-3 was ineffective. These data demonstrate the development and clinical utility of a novel liposomal formulationfor the treatment of prostate cancer.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 26 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 15%
Student > Bachelor 4 15%
Professor > Associate Professor 3 12%
Professor 3 12%
Lecturer 2 8%
Other 6 23%
Unknown 4 15%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 6 23%
Biochemistry, Genetics and Molecular Biology 3 12%
Medicine and Dentistry 3 12%
Chemistry 2 8%
Computer Science 1 4%
Other 5 19%
Unknown 6 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 202. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 March 2016.
All research outputs
#194,412
of 25,374,917 outputs
Outputs from Nanomedicine: Nanotechnology, Biology and Medicine
#5
of 1,520 outputs
Outputs of similar age
#3,375
of 312,895 outputs
Outputs of similar age from Nanomedicine: Nanotechnology, Biology and Medicine
#1
of 60 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,520 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,895 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.